NO20073370L - Kombinasjoner som innbefatter epotiloner og proteintyrosinkinaseinhibitorer og farmasoytiske anvendelser derav - Google Patents

Kombinasjoner som innbefatter epotiloner og proteintyrosinkinaseinhibitorer og farmasoytiske anvendelser derav

Info

Publication number
NO20073370L
NO20073370L NO20073370A NO20073370A NO20073370L NO 20073370 L NO20073370 L NO 20073370L NO 20073370 A NO20073370 A NO 20073370A NO 20073370 A NO20073370 A NO 20073370A NO 20073370 L NO20073370 L NO 20073370L
Authority
NO
Norway
Prior art keywords
tyrosine kinase
protein tyrosine
kinase inhibitors
pharmaceutical applications
combinations including
Prior art date
Application number
NO20073370A
Other languages
English (en)
Norwegian (no)
Inventor
Paul M J Mcsheehy
Jerry Min-Jian Huang
Anandhi Ranganathan Johri
Ronald Richard Linnartz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36118322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073370(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20073370L publication Critical patent/NO20073370L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20073370A 2004-11-30 2007-06-29 Kombinasjoner som innbefatter epotiloner og proteintyrosinkinaseinhibitorer og farmasoytiske anvendelser derav NO20073370L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63183704P 2004-11-30 2004-11-30
PCT/US2005/042975 WO2006060331A1 (en) 2004-11-30 2005-11-28 Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
NO20073370L true NO20073370L (no) 2007-06-29

Family

ID=36118322

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073370A NO20073370L (no) 2004-11-30 2007-06-29 Kombinasjoner som innbefatter epotiloner og proteintyrosinkinaseinhibitorer og farmasoytiske anvendelser derav

Country Status (29)

Country Link
US (2) US20080139587A1 (hr)
EP (1) EP1819331B1 (hr)
JP (1) JP2008521826A (hr)
KR (1) KR20070088653A (hr)
CN (1) CN101065127A (hr)
AT (1) ATE445398T1 (hr)
AU (1) AU2005312061B2 (hr)
BR (1) BRPI0518733A2 (hr)
CA (1) CA2584163A1 (hr)
CY (1) CY1110559T1 (hr)
DE (1) DE602005017181D1 (hr)
DK (1) DK1819331T3 (hr)
ES (1) ES2333348T3 (hr)
HK (1) HK1109059A1 (hr)
HR (1) HRP20100012T1 (hr)
IL (1) IL183138A (hr)
JO (1) JO2596B1 (hr)
MA (1) MA29032B1 (hr)
MX (1) MX2007006371A (hr)
NO (1) NO20073370L (hr)
NZ (1) NZ554552A (hr)
PL (1) PL1819331T3 (hr)
PT (1) PT1819331E (hr)
RU (1) RU2423980C2 (hr)
SI (1) SI1819331T1 (hr)
TN (1) TNSN07212A1 (hr)
TW (1) TW200630091A (hr)
WO (1) WO2006060331A1 (hr)
ZA (1) ZA200703196B (hr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2503888A4 (en) 2009-11-23 2015-07-29 Cerulean Pharma Inc POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
CN102134246A (zh) * 2011-01-06 2011-07-27 王文怡 一种埃博霉素衍生物及其制备和药物应用
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
US9738643B2 (en) 2012-08-06 2017-08-22 Duke University Substituted indazoles for targeting Hsp90
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
WO2020023628A1 (en) 2018-07-24 2020-01-30 Hygia Pharmaceuticals, Llc Compounds, derivatives, and analogs for cancer
WO2021185844A1 (en) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021233534A1 (en) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022047259A1 (en) 2020-08-28 2022-03-03 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
GB2617409B (en) 2022-04-27 2024-06-26 Cancertain Ltd Method for predicting responsiveness to therapy
WO2024030441A1 (en) 2022-08-02 2024-02-08 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US20040034026A1 (en) * 2000-11-22 2004-02-19 Wood Jeannette M Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
AU2002308218B2 (en) * 2001-02-27 2005-11-10 Novartis Ag Combination comprising a signal transduction inhibitor and an epothilone derivative
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
ES2295428T3 (es) * 2001-10-25 2008-04-16 Novartis Ag Combinaciones que comprenden un inhibidor selectivo de ciclooxigenasa-2.
PL372070A1 (en) * 2002-06-10 2005-07-11 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Also Published As

Publication number Publication date
EP1819331A1 (en) 2007-08-22
MA29032B1 (fr) 2007-11-01
DE602005017181D1 (de) 2009-11-26
PT1819331E (pt) 2009-11-30
NZ554552A (en) 2011-05-27
DK1819331T3 (da) 2010-01-04
AU2005312061B2 (en) 2009-09-03
PL1819331T3 (pl) 2010-03-31
IL183138A (en) 2011-03-31
TNSN07212A1 (en) 2008-11-21
CA2584163A1 (en) 2006-06-08
JO2596B1 (en) 2011-02-27
US20110190312A1 (en) 2011-08-04
ATE445398T1 (de) 2009-10-15
HRP20100012T1 (hr) 2010-02-28
IL183138A0 (en) 2008-04-13
SI1819331T1 (sl) 2010-02-26
BRPI0518733A2 (pt) 2008-12-02
TW200630091A (en) 2006-09-01
RU2423980C2 (ru) 2011-07-20
CN101065127A (zh) 2007-10-31
ES2333348T3 (es) 2010-02-19
WO2006060331A1 (en) 2006-06-08
AU2005312061A1 (en) 2006-06-08
EP1819331B1 (en) 2009-10-14
KR20070088653A (ko) 2007-08-29
JP2008521826A (ja) 2008-06-26
HK1109059A1 (en) 2008-05-30
MX2007006371A (es) 2007-06-20
RU2007124492A (ru) 2009-04-10
CY1110559T1 (el) 2015-04-29
US20080139587A1 (en) 2008-06-12
ZA200703196B (en) 2009-08-26

Similar Documents

Publication Publication Date Title
NO20073370L (no) Kombinasjoner som innbefatter epotiloner og proteintyrosinkinaseinhibitorer og farmasoytiske anvendelser derav
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
ATE527253T1 (de) Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer
CR20120244A (es) Inhibidores de la tirosina quinasa de bruton
ATE457301T1 (de) Substituierte aryl-acylthioharnstoffe und verwandte verbindungen, virenreplikationshemmer
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
DK1784396T3 (da) Pyrazol-substituerede aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
NO20090628L (no) Pyridizinon derivativater
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
EA200801430A1 (ru) Производные триазола
WO2005108416A3 (en) Myosin light chain kinase inhibitors and their use
DK1912954T3 (da) Hidtil ukendte cysteinproteaseinhibitorer og deres terapeutiske applikationer
ITRM20030572A1 (it) Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune.
CL2007001737A1 (es) Compuestos derivados de cianopiridinas; inhibidores de proteina quinasa;composicion farmaceutica;y uso para el tratamiento o inhibicion de un trastorno mediado por una proteina quinasa,tal como enfermedad autoinmune e inflamatoria.
IS8102A (is) Samsetning ras-farnesýltransferasatálma, sýklódextríns og etanóls

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application